Omeros (OMER) Share-based Compensation (2010 - 2026)
Omeros (OMER) reported Share-based Compensation of $1.9 million for Q1 2026, down 22.99% on a YoY basis from $2.5 million in Q1 2025, and up 9.0% sequentially from $1.7 million in Q4 2025.
Omeros (OMER) Share-based Compensation (2010 - 2026) Analysis & Trends
Omeros (OMER) has 17 years of Share-based Compensation data on file, last reported at $1.9 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 22.99% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.5 million (down 14.37% YoY), and the FY2025 full-year result was $12.1 million, down 3.2% from the prior year.
- Share-based Compensation rose to $1.9 million in Q1 2026, from $1.7 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $3.9 million in Q1 2022 to a low of $856000.0 in Q3 2025.
- A 5-year average of $2.5 million and a median of $2.7 million in 2024 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation plunged 67.14% in 2024 and gained 21.54% in 2025, its largest moves.
- Tracing OMER's Share-based Compensation over 5 years: stood at $3.3 million in 2022, then retreated by 17.56% to $2.7 million in 2023, then declined by 9.85% to $2.4 million in 2024, then decreased by 28.57% to $1.7 million in 2025, then advanced by 9.0% to $1.9 million in 2026.
- Business Quant data shows OMER's Share-based Compensation at $1.9 million in Q1 2026, $1.7 million in Q4 2025, and $856000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Omeros | 739.31 Mn | 739.31 Mn | 9.31 Mn | 1.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.89 Mn |
| Mar 31, 2026 | 1.89 Mn |
| Dec 31, 2025 | 1.73 Mn |
| Dec 31, 2025 | 1.73 Mn |
| Sep 30, 2025 | 856,000.00 |
| Sep 30, 2025 | 856,000.00 |
| Jun 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | 2.07 Mn |
| Mar 31, 2025 | 2.45 Mn |
| Mar 31, 2025 | 2.45 Mn |
| Dec 31, 2024 | 2.43 Mn |
| Dec 31, 2024 | 2.43 Mn |
| Sep 30, 2024 | 1.06 Mn |
| Sep 30, 2024 | 1.06 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 2.66 Mn |
| Mar 31, 2024 | 2.66 Mn |
| Dec 31, 2023 | 2.69 Mn |
| Dec 31, 2023 | 2.69 Mn |